# nature portfolio

Corresponding author(s):	Bongjun Kim, Jae-II Park
Last updated by author(s):	Oct 2, 2024

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<b>~</b> .			
Sτ	`at	ict	icc

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	$\boxtimes$	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	$\boxtimes$	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	$\boxtimes$	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$		A description of all covariates tested
	$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
$\boxtimes$		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\times$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\times$		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	$\boxtimes$	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

#### Software and code

Policy information about availability of computer code

Data collection

GSE141259; GSE135893

Data analysis

The code used to reproduce the analyses described in this manuscript can be accessed via Zonodo (https://zenodo.org/records/13871131) and will also be available upon request. Softwares and Packages used in this study were described below.

Softwares R 4.0.3 Python 3.9.7

R packages
Seurat 4.1.0
CytoTRACE 0.3.3
scProportionTest 0.0.0.9000
fgsea 1.16.0
dplyr 1.0.8
ggplot2 3.3.5
matrix 1.4-0
ade4 1.7-18
presto 1.0.0
SeuratDisk 0.0.0.9019
SeuratWrappers 0.3.0

ulosa 1.0.2	
plot 1.1.1	
oSeq 1.2.6	
ubr 0.4.0	
ustViz 1.3.8	
on Packages	
elo 0.2.4	
enic 0.11.2	
das 1.3.3	
py 1.8.1	
ppy 1.21.2	
ty 1.7.1	
npy 3.0.6	
data 0.7.6	
p 0.5.2	
t-learn 1.0.2	
smodels 0.13.1	
non-igraph 0.9.9	
ndescent 0.5.6	

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

scRNA-seq data are available via the Gene Expression Omnibus (GSE205815; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205815).

#### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

 ☑ Life sciences
 ☐ Behavioural & social sciences
 ☐ Ecological, evolutionary & environmental sciences

 $For a \ reference \ copy \ of the \ document \ with \ all \ sections, see \ \underline{nature.com/documents/nr-reporting-summary-flat.pdf}$ 

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

For all in vitro experiment, the number of samples sizes are three or above. For animal studies, sample sizes were estimated by power calculation.

Data exclusions	No samples or animals were excluded. Also, the criteria were not pre-established in experiments.	
Replication	All experiments were performed using at least three biological replicas unless specified. All experiments were successfully replicated.	
Randomization	All mice were randomized in each groups.	
Blinding	N/A	
keportin	g for specific materials, systems and methods	
	on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, sed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
sterr of method list	eu is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & exp	perimental systems Methods	
/a Involved in th	n/a Involved in the study	
Antibodies		
Eukaryotic	cell lines Flow cytometry	
Eukaryotic Palaeontol	ogy and archaeology MRI-based neuroimaging	
	d other organisms	
Animals an Clinical dat Dual use re	a	
Dual use re	esearch of concern	
⊠ Plants		
ntibodies		
	IHC	
Antibodies used	anti-PCLAF (Abcam, ab26255, 1:100) anti-PCLAF (Abcam, ab56773, 1:100) anti-PCLAF (Abcam, ab5694, 1:200) anti-RAGE (R&D, MAB1179-100, 1:100) anti-SPC (Abcam, ab40879, 1:200) anti-SCGBIA1 (Abcam, ab40873, 1:200) anti-CCBIA1 (Abcam, ab40873, 1:200) anti-HOPX (Santacruz, sc-398703, 1:100) anti-HOPX (Santacruz, sc-398703, 1:100) anti-CLIC4 (Cell signaling, 12644S, 1:200) anti-PSMAD3 (S423 + S425) (Abcam, ab52903, 1:200) anti-FLAG (Abcam, ab205606, 1:200) anti-FLAG (Abcam, ab205606, 1:200) anti-CC3 (Cell signaling, 9664s, 1:200) anti-CC3 (Cell signaling, 9664s, 1:200) anti-CN1 (BD, 610182, 1:200) anti-CN2 (R&D, AF1857-SP, 1:200) anti-CD45 (Abcam, ab10558, 1:100) anti-CD46 (Abcam, ab10558, 1:100) anti-CD47 (BD, 610078, 1:200)	
	anti-PCLAF (Abcam, ab226255, 1:200)	
Validation	Allantibodieswerecommerciallyvalidated(seemanufacturer'swebsitelinkbelow) anti-PCLAF (Abcam, ab226255) https://www.abcam.com/products/primary-antibodies/kiaa0101-antibody-ab2anti-PCLAF (Abcam, ab56773, anti-PCLAF (Abcam, ab56773, 1:100) https://www.abcam.com/products/primary-antibodies/kiaa0101-antibody-ab56773.html anti-SMA (Abcam, ab5694) https://www.abcam.com/products/primary-antibodies/alpha-smooth-muscle-actin-antibody-ab5694.html anti-RAGE (R&D, MAB1179-100) https://www.rndsystems.com/products/mouse-rat-rage-antibody-175410_mab1179 anti-SPC (Abcam, ab40879)	
	https://www.abcam.com/products/primary-antibodies/prosurfactant-protein-c-antibody-ab40879.html anti-SCGB1A1 (Abcam, ab40873)	

https://www.abcam.com/products/primary-antibodies/uteroglobin-antibody-ab40873.html

anti-Ac-TUB (Sigma, T6793) https://www.sigmaaldrich.com/US/en/product/sigma/t6793 anti-HOPX (Santacruz, sc-398703)

```
https://www.scbt.com/p/hop-antibody-e-1
```

anti-CLIC4 (Cell signaling, 12644S)

https://www.cellsignal.com/products/primary-antibodies/clic4-d2a7d-rabbit-mab/12644? requestid=2136261

anti-p-SMAD3 (S423 + S425) (Abcam, ab52903)

https://www.abcam.com/products/primary-antibodies/smad3-phospho-s423--s425-antibody-ep823y-ab52903.html

anti-KI67 (Cell signaling, 9449S)

https://www.cellsignal.com/products/primary-antibodies/ki-67-8d5-mouse-mab/9449

anti-FLAG (Abcam, ab205606)

https://www.abcam.com/products/primary-antibodies/ddddk-tag-binds-to-flag-tag-sequence-antibody-epr20018-251-

ab205606.html

anti-CC3 (Cell signaling, 9664s)

https://www.cellsignal.com/products/primary-antibodies/cleaved-caspase-3-asp175-5a1e-rabbit-mab/9664

anti-CDH1 (BD, 610182)

https://www.bdbiosciences.com/en-us/products/reagents/microscopy-imaging-reagents/immunofluorescence-reagents/purified-

mouse-anti-e-cadherin.610182

anti-KRT8 (DSHB, DSHB TROMA-I)

https://dshb.biology.uiowa.edu/TROMA-I

anti-LCN2 (R&D, AF1857-SP) https://www.rndsystems.com/products/mouse-lipocalin-2-ngal-antibody af1857

anti-CD45 (Abcam, ab10558)

https://www.abcam.com/products/primary-antibodies/cd45-antibody-ab10558.html

anti-CD44 (BD, 550538)

https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/ purified-rat-anti-mouse-cd44.550538

anti-FN (BD, 610078)

https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/products/reagents/flow-cytometry-reagents/single-color-antibodies-ruo/products/single-color-antibodies-ruo/products/single-color-apurified-mouse-anti-fibronectin.610078

anti-FLAG (Sigma, F3040)

https://www.sigmaaldrich.com/US/en/product/sigma/f3040

#### Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

H358 lung adenocarcinoma cell line was purchased from ATCC (ATCC, CRL5807). Cell line source(s)

Authentication We have not performed additional authentication.

Cells were negative for mycoplasma contamination Mycoplasma contamination

Commonly misidentified lines (See ICLAC register)

No commonly misidentified cell lines were used in this study

### Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Wild type C57BL/6J mice were purchased from Jackson laboratory (RRID: IMSR\_JAX:000664). Laboratory animals

Pclaf KO mice were generated in previous study. (2018. Developmental Cell. DOI: https://doi.org/10.1016/j.devcel.2018.02.010).

Pclaf-LacZ-neo mice were purchased from EMMA (EMMA ID: EM09820). CMV-Cre mice were purchased from Jackson laboratory (IMSR JAX:006054).

Rosa26-Flp1 mice were purchased from Jackson laboratory (RRID:IMSR JAX:009086).

Sftpc-CreERT2; Rosa26-Sun1GFP mice were kindly provided by Dr. Jichao Chen (M.D. Anderson Cancer Center) Pclaf-LacZ mice were established in this study by breeding Pclaf-LacZ-neo mice with CMV-Cre driver mice.

Pclaf-fl/fl mice were established in this study by breeding Pclaf-LacZ-neo mice with Rosa26-Flp1 driver mice.

Wild animals The study did not involve wild animals

This information has not been collected, as it is irrelevant to our study. Reporting on sex

Field-collected samples The study did not involve field-collected samples.

All mouse experiments were approved by the MD Anderson Institutional Animal Care and Use Committee and performed under MD Ethics oversight

Anderson guidelines and the Association for Assessment and Accreditation of Laboratory Animal Care international standards.

Note that full information on the approval of the study protocol must also be provided in the manuscript.